Abstract:Background and Objectives To assess the clinical practice applicability of autoimmune encephalitis (AE) criteria (2016). Methods Medical records of 538 adults diagnosed with AE or related autoimmune encephalopathy at Mayo Clinic (not including pure movement disorders) were reviewed and AE guideline criteria applied. Results Of 538 patients, 288 were male (52%). The median symptom onset age was 55 years (range, 11–97 years; 16 had onset as children). All had other non-AE diagnoses reasonably excluded. Of 538 patients, 361 (67%) met at least possible criteria, having all 3 of subacute onset; memory deficits, altered mental status or psychiatric symptoms, and ≥1 supportive feature (new focal objective CNS finding, N = 285; new-onset seizures, N = 283; supportive MRI findings, N = 251; or CSF pleocytosis, N = 160). Of 361 patients, AE subgroups were as follows: definite AE (N = 221, 61%, [87% AE-specific IgG positive]), probable seronegative AE (N = 18, 5%), Hashimoto encephalopathy (N = 20, 6%), or possible AE not otherwise categorizable (N = 102, 28%). The 221 patients with definite AE had limbic encephalitis (N = 127, 57%), anti–NMDA-R encephalitis (N = 32, 15%), ADEM (N = 8, 4%), or other AE-specific IgG defined (N = 54, 24%). The 3 most common definite AE-IgGs detected were as follows: LGI1 (76, 34%), NMDA-R (32, 16%), and high-titer GAD65 (23, 12%). The remaining 177 patients (33%) not meeting possible AE criteria had the following: seizures only (65, 12% of all 538 patients), brainstem encephalitis without supratentorial findings (55, 10%; none had Bickerstaff encephalitis), or other (57, 11%). Those 57 "others" lacked sufficient supportive clinical, radiologic, or CSF findings (N = 26), had insidious or initially episodic onset of otherwise typical disorders (N = 21), or had atypical syndromes without clearcut memory deficits, altered mental status, or psychiatric symptoms (N = 10). Fifteen of 57 were AE-specific IgG positive (26%). Among the remaining 42, evidence of other organ-specific autoimmunity (mostly thyroid) was encountered in 31 (74%, ≥1 coexisting autoimmune disease [21, 50%] or ≥1 non–AE-specific antibodies detected [23, 53%]), and all but 1 had an objective immunotherapy response (97%). Discussion The 2016 AE guidelines permit autoimmune causation assessment in subacute encephalopathy and are highly specific. Inclusion could be improved by incorporating AE-IgG–positive patients with isolated seizures or brainstem disorders. Some patients with atypical presentations but with findings supportive of autoimmunity may be immune therapy responsive.

Autoimmune encephalitis in a resource-limited public health setting: a case series analysis

Clinical Features and Inflammatory Markers in Autoimmune Encephalitis Associated With Antibodies Against Neuronal Surface in Brazilian Patients

Brazilian autoimmune encephalitis network (BrAIN): antibody profile and clinical characteristics from a multicenter study

Autoimmune Encephalitis: Insights Into Immune-Mediated Central Nervous System Injury

Autoimmune encephalitis and immune therapy: lessons from Argentina

Neurological syndromes and potential triggers associated with antibodies to neuronal surface antigens

Clinical manifestations and immunomodulatory treatment experiences in psychiatric patients with suspected autoimmune encephalitis: a case series of 91 patients from Germany

Long-term outcomes in antibody-negative autoimmune encephalitis: a retrospective study

Autoimmune encephalitis in Israeli children – A retrospective nationwide study

Brazilian consensus recommendations on the diagnosis and treatment of autoimmune encephalitis in the adult and pediatric populations

Prognostic factors and treatment outcomes in pediatric autoimmune encephalitis: a multicenter study

Analysis of Clinical Characteristics of Autoimmune Encephalitis: 17 Cases Report

Characteristics and Prognosis of Autoimmune Encephalitis in the East of China: A Multi-Center Study

Autoimmune Encephalitis Criteria in Clinical Practice

Electroencephalographic outcomes and predictors of epilepsy in autoimmune encephalitis

Residual symptoms and long-term outcomes after all-cause autoimmune encephalitis in adults

Immunotherapy in Probable autoimmune encephalitis without detected autoantibody

Anti-GABAB Receptor Autoimmune Encephalitis: A Report of a Rare Case in Central America

Clinical features and immunotherapy outcomes in antibody-negative autoimmune encephalitis: a retrospective case-control study

A-280 Residual Cognitive Weaknesses in a Case of Treated Seronegative Autoimmune Encephalitis

Autoimmune and infectious encephalitis: development of a discriminative tool for early diagnosis and initiation of therapy